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PENGAWALATURAN TELOMERASE TRANSKRIPTASE BERBALIK 
(TERT) OLEH GEN GABUNGAN LEUKEMIA AML1/ETO 
 
ABSTRAK 
 Translokasi kromosom t (8; 21) adalah suatu aberasi kromosom yang biasa 
berlaku dalam penyakit akut mieloid leukaemia (AML) de novo. Kebarangkalian 
translokasi ini berlaku dalam AML adalah sebanyak 15%. Translokasi ini 
menghasilkan gen bergabung onko-protein AML1-ETO (juga dikenali sebagai AML1 
/ MTG8, RUNX1 / ETO atau RUNX1 / RUNX1T1). Penyelidikan mengenai 
translokasi ini giat dijalankan. Pesakit dengan translokasi kromosom ini pada 
kebiasaan dilaporkan mempunyai prognosis klinikal yang lebih baik. Kajian terkini 
menunjukkan bahawa supresi AML-ETO akan menyebabkan pengurangan expresi 
enzim telomerase transkriptase berbalik (TERT). Walau bagaimanapun, mekanisme 
bagaimana supresi ini berlaku masih tidak dapat dijelaskan secara mendalam hingga 
kini. Oleh itu, tujuan kajian ini adalah untuk mengkaji peranan AML-ETO dalam 
pengawalaturan TERT. Kajian ini mengemukakan hipotesis bahawa AML-ETO 
mengawalatur TERT melalui tapak jalan CDKN1B (p27) / RB-E2F l. Hipotesis ini 
telah diuji secara eksperimen melalui kaedah perencatan gen yang menggunakan 
siRNA. Tiga siRNA yang berbeza iaitu siAGF1, siCDKN1B dan siSKP2 serta 
kombinasinya telah digunakan. Eksperimen dengan siAGF1 menunjukkan bahawa 
tahap AML-ETO dan TERT berkurang pada peringkat RNA dan protein. Protein lain 
yang menunjukkan pengurangan termasuk RB, E2F1 dan SKP2. Walau 
bagaimanapun, terdapat peningkatan protein CDKN1B (p27). Jumlah sel di fasa G1 
dalam kitaran sel juga bertambah. Pemerhatian lain yang boleh dikaitkan dengan 
kehilangan TERT seperti pengurangan keupayaan klonogenik dan peningkatan kadar 
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penuaan sel telah diperhatikan dengan jelas. Eksperimen menggunakan siCDKN1B 
menujukkan penurunan tahap CDKN1B (p27) pada peringkat RNA dan protein. 
Jumlah protein TERT, AML/ETO, SKP2, RB dan E2F1 protein meningkat dengan 
ketara. Keupayaan klonogenik sel-sel tidak terjejas dan peratusan sel uzur berkurang. 
Eksperimen menggunakan siSKP2 menujukkan hasil yang memberangsangkan 
dimana kesan experimen ini adalah selaras dengan kesan yang ditunjukkan semasa 
siAGF1 digunakan Walau bagaimanapun, kesannya tidak mencapai tahap yang 
ditunjukkan oleh experimen yang menggunakan siAGF1. Kesan pengurangan TERT, 
AML-ETO dan SKP2 serta peningkatan paras CDKN1B dapat diperhatikan. 
Pengurangan keupayaan klonogenik serta peningkatan kadar penuaan sekali lagi boleh 
dikaitkan dengan kehilangan TERT. Secara rumusan, terdapat bukti jelas yang 
menunjukkan bahawa AML-ETO mengawalatur TERT melalui paksi SKP2/p27/ RB-
E2F. 
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REGULATION OF TELOMERASE REVERSE TRANSCRIPTASE (TERT) 
BY THE LEUKAEMIC FUSION GENE AML1/ETO 
 
ABSTRACT 
 The chromosomal translocation t(8;21) is a common chromosomal aberration 
that occurs in up to about 15% of all de novo acute myeloid leukaemia (AML) cases. 
This translocation results in the formation of a fusion onco-protein known as AML1-
ETO (also known as AML1/MTG8, RUNX1/ETO or RUNX1/RUNX1T1). Much 
research has been done regarding this chromosomal aberration. Patients with this 
chromosomal translocation tend to have better clinical prognosis. Recent studies have 
shown that suppression of AML/ETO caused a reduction in telomerase reverse 
transcriptase (TERT) levels. Nevertheless, the molecular mechanism by which this 
fusion onco-protein governs TERT regulation is still unknown. Therefore, the aim of 
this study was to investigate the role of AML/ETO in TERT regulation. It was 
hypothesized that AML-ETO regulates TERT via the CDKN1B (p27)/RB-E2F 
pathway. This hypothesis was experimentally tested using a siRNA mediated gene 
knockdown approach. Three different siRNA’s namely siAGF1, siCDKN1B and 
siSKP2 and combinations thereof were utilized. Gene knockdown experiments using 
siAGF1 showed that AML-ETO and TERT levels were reduced at the RNA and 
protein level. Other proteins that showed reductions include RB, E2F1 and SKP2. 
There was also an accumulation of CDKN1B (p27) protein. A G1 phase arrest in the 
cell cycle was observed too. Other consequential observations linked to TERT loss 
such as reduced clonogenicity and increased senescence were evident as well. 
Knockdown experiments utilizing siCDKN1B exhibited decreased levels of CDKN1B 
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(p27) at the RNA and protein level. Levels of TERT, AML-ETO, SKP2, RB and E2F1 
proteins showed marked increase. Clonogenicity of the cells were not affected and 
percentages of senescent cells were reduced. Interestingly, experiments with siSKP2 
mirrored the knockdown effects of siAGF1 albeit to a lower extent. This includes 
reductions in TERT, AML-ETO and SKP2 levels, increase in CDKN1B levels, 
reduced clonogenicity and increased senescence. This again could be attributed to 
TERT loss. Overall, it is clearly shown that AML-ETO regulates TERT via the 
SKP2/p27/RB-E2F axis. 
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                                 Chapter 1: INTRODUCTION 
 
1.1 Research Background 
 Telomeres are guanine rich DNA tandem repeats formed by special chromatin 
structures at the ends of all eukaryotes with linear chromosomes. This is to protect 
chromosomes from fusion, recombination and degradation (Blackburn, 2001; Hiyama 
& Hiyama, 2009).  Telomeres are about 10-15 Kb in length in human somatic cells 
and can be up to 40 Kb in mice (Wright & Shay, 2005; Blasco, 2005).  Due to the semi 
conservative nature of DNA replication, telomeres gradually shorten after each cell 
cycle. This replicative process which eventually causes cell aging and senescence is 
commonly known as the ‘end replication’ problem. A unique enzyme known as 
telomerase overcomes this problem by providing a template and catalytic subunit to 
add telomeric repeat sequences thus maintaining telomere lengths (Depcrynski et al., 
2009).  
 Telomerase is a large ribonucleoprotein that is composed of at least two 
important components; the catalytic subunit (TERT) which has reverse transcriptase 
activity and the RNA component (TERC- also termed hTR) which acts as template for 
the synthesis of telomeric tandem repeats by TERT (Parkinson et al., 2008). The other 
component is a RNA binding protein known as dyskerin which is encoded by the 
DKC1 gene (Mitchell et al., 1999; Cao et al., 2008). TERC is ubiquitously expressed 
in most cells (Feng et al., 1995; Avilion et al., 1996) while TERT expression is low in 
normal somatic cells but up-regulated in tumor cells (Killian et al., 1997; Nakamura 
et al. 1997). 
 
  
2 
 
 Telomerase has been drawing much attention as it has been implicated in over 
90% of all human cancers thus making it an ideal candidate for diagnostic and 
therapeutic purposes (Shay & Bacchetti, 197; Depcrynski et al., 2009). Note worthily, 
various studies have shown that telomerase is elevated in Acute Myelogenous 
leukemia (AML) as well (Counter et al., 1995; Ohyashiki et al., 1997; Engelhardt et 
al., 2000). 
 
 Acute Myeloid Leukemia (AML) is a clonal disorder arising from the genetic 
abnormalities that occur in hematopoietic stem cells and hampers the ability of these 
cells to differentiate into erythrocytes, granulocytes and platelets. This eventually 
leads to the accumulation of abnormal leukemic cells known as blasts. AML is highly 
aggressive and heterogeneous in nature (Fialkow et al., 1981, Sawyers et al., 1991, 
Vardiman et al., 2002).  In Malaysia, the age standardized incidence for AML is 2.9 
per 100,000 of the population (Zainal & Nor Saleha, 2011; Meng et al., 2013). 
 
 One of the hallmarks of AML are cytogenetic abnormalities. Common 
cytogenetic abnormalities include AML with t(8;21) (q22;q22.3); RUNX1/RUNX1T1 
(AML1/ETO or RUNX1/MTG8) which occurs in 8-12% of all de novo AMLs 
(Swansbury et al.,1994), AML inv(16) (p13.1q22) or t(16;16) (p13.1;q22); 
CBFb/MYH11 which occurs in 5-13% of all de novo AMLs (Kalwinsky et al.,1990, 
Liu et al.,1995) and Acute Promyelocytic Leukemia with t(15;17) (q22;q21); 
PML/RARA which occurs in 5-13% of all de novo AMLs (Douer et al.,1996). 
 
 Translocation AML t(8;21) (q22;q22.3) fuses the AML1[RUNX1, PEBP2αB, 
CBFα2] gene on chromosome 21 to the almost complete open reading frame of MTG8 
[ETO, CBF2T1] on chromosome 8 resulting in a fusion protein AML1/ETO also 
known as AML1/ETO, RUNX1/RUNX1T1, RUNX1/MTG8, or RUNX1-CBFA2T1 
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(Heidenreich et al., 2003; Martinez et al., 2004). This fusion protein has been reported 
in up to 40% of all AML subtype M2 (FAB classification) and 12-15% of de novo 
AML in general. Smaller proportions have been reported in AML subtype M0, M1 
and M4 as well (Peterson & Zhang, 2004).  AML1/ETO has been known to directly 
bind to transcription factors such as SMAD3, C/EBPα or vitamin D receptor thus 
affecting signal transduction pathway that govern cell proliferation and differentiation 
(Westendorf et al.,1998; Jakubowiak et al., 2000; Pabst et al., 2001b; Puccetti et al., 
2002; Vangala et al., 2003). This translocation merits further investigation as patients 
with this translocation tend to have a better prognosis and complete remission rates 
(Ferrara & Vecchio, 2002). 
 
 One interesting fact to note is that AML1/ETO by itself cannot cause leukemia 
as further secondary mutations are required for leukemia development (Rhoades et al., 
2000; Buchholz et al., 2000; Yuan et al., 2001; Schwieger et al., 2002; Grisolano et 
al., 2003). Furthermore, the interaction of AML1/ETO in molecular pathways 
associated with leukemogenesis is not fully understood despite numerous studies 
(Peterson & Zhang, 2004).  
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1.2 Rationale and importance of the study. 
 
 Recent studies by Gessner et al., 2010 and Ptasinska et al. 2012 have shown 
that AML1/ETO gene knockdown caused a reduction of TERT transcript levels in AML 
t(8;21) positive cell lines.  A decrease in TERT protein levels and telomere shortening 
was observed as well.  These observations show that AML/ETO regulates telomerase 
reverse transcriptase (TERT); the catalytic subunit of telomerase which is a key 
component for self-renewal. Nevertheless, the mechanism by which this fusion protein 
mediates TERT regulation is still unknown. Therefore, the aim of this study will be to 
elucidate the role of AML1/ETO in TERT regulation.  
 
 Owing to the fact that TERT expression and AML1/ETO are both tightly linked 
to the cell cycle (Martinez et al., 2004, Gizard et al., 2008), it is highly plausible that 
AML1/ETO interacts with genes such as retinoblastoma (RB), E2F transcription 
factors and cyclin dependent kinase (CDK) inhibitors which are involved in cell cyle 
regulation (Harbour & Dean, 2001; Sherr & Roberts, 2004; Blasco, 2005). Besides 
AML1/ETO, another gene that will be the focal point of this study is the CDK inhibitor 
p27KIP1. This gene was chosen because p27KIP1 levels are influenced by AML1/ETO 
(Martinez et al., 2004) and it has also been postulated to be involved in TERT 
regulation through interactions with Rb and E2F (Depcrynski et al.,2009). Therefore, 
it is possible that AML1/ETO interacts with p27 KIP1 to regulate TERT expression. The 
postulation above is presented in a nutshell in Figure 1.1 
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 Another important aspect of this study would be to look at the consequences 
of TERT loss on AML t(8;21) cell lines. This is because events related to cell cycle 
growth arrest and cellular senescence that were observed in AML/ETO knockdowns 
(Martinez et al., 2004; Gessner et al. 2010) could have been caused by the low levels 
of TERT.  
 This study is important as it encompasses a key question in the self-renewal 
capability of leukemic stem cells and cancer stem cells in general. It is hoped that some 
insights would be gained in relation to the molecular events that govern self- renewal 
mechanisms in leukemic cancer stem cells through this study. Furthermore, 
understanding these mechanisms could lead to the discovery of other regulatory 
networks that interact with AML1/ETO to regulate TERT and provide some insights 
regarding the molecular pathogenesis of Acute Myeloid Leukaemia. New potential 
drug targets for Acute Myeloid Leukaemia could be discovered from these regulatory 
networks. This in turn could certainly open new doors for new therapeutic approaches 
and cell based therapies which would greatly improve the clinical outcome of 
leukaemic patients. 
 
 
Figure 1.1: Postulation of TERT regulation by AML1/ETO. It is postulated that 
AML/ETO regulates TERT via the p27- RB/E2F axis 
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1.3 Hypothesis and objective of the study 
 
1.3.1 Hypothesis 
Null Hypothesis 
AML/ETO does not regulate TERT via the p27-RB/E2F axis 
 
Alternative Hypothesis (Hypothesis of this study) 
AML1/ETO regulates TERT via the p27-RB/E2F axis 
 
1.3.2 Objective of the study 
 
 The main objective of this study is to elucidate the mechanism of TERT 
regulation by the leukaemic fusion gene AML1/ETO.  The specific objectives are as 
follows; 
1. To suppress AML1/ETO, CDKN1B and SKP2 genes in t (8;21) AML cell lines using        
small interfering RNAs (siRNAs) in order to understand the underlying mechanism of 
TERT regulation by AML1/ETO 
2. To investigate the effects of AML1/ETO, CDKN1B and SKP2 suppression on    
AML/ETO, TERT, p27, E2F, RB and SKP2 genes and proteins 
3. To investigate the effects of TERT loss on cell cycle, clonogenecity and cellular 
senescence after AML1/ETO, CDKN1B and SKP2 supression   
4. To study interactions between AML1/ETO, TERT, p27, E2F, RB and SKP2 and 
develop a model to explain the mechanism of TERT regulation by AML1/ETO. 
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CHAPTER 2: LITERATURE REVIEW 
 
 
2.1 Acute Myeloid Leukaemia (AML) 
 
 Acute myeloid leukaemia (AML) is a malignant disease which stems from 
clonal disorder of haematopoietic stem cells. It usually causes a diﬀerentiation block 
which results in accumulation of immature blood cells (blasts) in the bone marrow. 
Production of healthy haemopoietic elements are greatly reduced and haematopoiesis 
is hampered (Ferarra & Schifer, 2013). The abnormal accumulation of blast is caused 
by various inherited and acquired genetic mutations which disrupt normal mechanisms 
of self-renewal, proliferation and differentiation (Gilliland, 1998; Dash & Gilliland 
2001; Gilliland & Tallman, 2002). 
 Several predisposing environmental factors and inherited genetic disorders 
have been associated with the development of AML (Rubnitz et al., 2010). 
Environmental factors include exposure to chemotherapy and ionizing radiations, 
petroleum products, benzene (organic solvents), pesticides (organophosphates) and 
herbicides (Yin, et al., 1996; McBride, 1997; Korte et al., 2000; Mills & Zahm, 2001). 
Inherited genetic disorders that have been implicated in AML development include 
Down syndrome, Fanconi anaemia, Schwachman-Diamond Syndrome, Diamond-
Blackfan syndrome, neurofibromatosis syndrome, noonan syndrome and dyskeratosis 
congenita among others (Bader & Miller, 1978; Bader-Meunier et al., 1997; 
Rosenberg et al., 2003). 
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 AML afflicts about 3.8 per 100,000 people among the whites and about 3.2 per 
100 000 people among the Asian populations (Howlader et al., 2014). It is the most 
common form of acute leukaemia and is more prevalent in males than female amongst 
adults (Meng et al., 2013). Due to its heterogeneity, AML produces variable clinical 
outcomes or prognosis (Marcucci et al., 2011). 
2.1.1 Classification of AML 
  Two systems of AML classification are widely accepted globally. The first 
system is the French-American-British (FAB) system. This system is primarily based 
on the morphology of cells and status of cell maturation as well as differentiation 
(Bennett et al., 1985; Cheson, 1990).  
 The second system was introduced by the World Health Organization (WHO) 
in 2001. This system takes into account the morphology, cytogenetics, molecular 
genetics and immunologic properties of AML thus giving it more accuracy and 
prognostic validity (Vardiman et al., 2002). The WHO classification was last updated 
in 2008. In this latest update of the classification, AML was broadly classified into 
four different categories namely AML with recurrent genetic abnormalities, AML with 
myelodysplasia related changes, therapy related neoplasms and AML not otherwise 
specified-NOS (Vardiman et al., 2009).  
 AML classifications according to FAB and WHO systems are presented in 
Tables 2.1 and 2.2. 
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Table 2.1: AML classification according to French-American-British system. Table is 
taken from Tenen, 2003 
 
Table 2.2: AML classification according to WHO system. Table is based on     
Vardiman et al., 2009. 
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2.2 Cytogenetic Abnormalities in AML 
 
 One prominent feature of AML is the accumulation of cytogenetic 
abnormalities caused by chromosomal aberrations. In a large cohort multinational 
study carried out by United Kingdom Medical Research Council, over 54 types of 
cytogenetic abnormalities were discovered in a group of 5876 patients with AML. The 
age group of the patients ranged from 16-59 years of age. About 2432 patients (41%) 
exhibited normal karyotype. The rest had various types of chromosomal abberations. 
This included monosomy (e.g monosomy 3, 5, 7 and 9), trisomy (e.g trisomy 4, 6, 8, 
11, 21), deletions (e.g del 5q, del 7q, del 13q), additions (e.g add 5q, add 7q), and 
translocations [e.g t(8;21), t(15;17), t(9;11)] (Grimwade et al., 2010). Cytogenetic 
abnormalities serve as an important prognostic tool and can be widely classified into 
three different subgroups. This include those with favourable clinical outcome, 
intermediate clinical outcome and adverse or poor clinical outcome (Shipley & Butera, 
2009). 
 Chromosomal abnormalities t(8;21), t(15;17) and t(16;16) are usually 
associated with  good clinical prognosis (Grimwade & Hills, 2009).  Patients with 
t(8;21) and t(16;16) who have undergone chemotherapy with high doses of cytarabine 
had cure rates of more than 60% (Byrd et al., 2004; Bloomfield et al., 2004) while 
patients with t(15;17) who had undergone treatment with all-trans  retinoic acid 
(ATRA) had curable rates of up to 90% (Wang & Chen, 2008).  
 Patients with normal karyotype, t(9;11), del 7q, del 9q and other non-complex  
karyotype are usually placed in the intermediate group (Grimwade et al., 1998; Shipley 
& Butera, 2009).  Patients with these abnormalities have a worse prognosis than the 
first group but better if compared to the third group. 
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 Patients with chromosomal aberrations t(9;22), t(6;9), abnormal 3q26,  del 5q, 
t(11;17), t(3,3) and complex karyotype among others have the worst prognosis among 
all the groups (Ferrara & Schifer, 2013; Grimwade et al.,1998; Shipley and Butera, 
2009). Complex karyotype are defined as patients with 4 or more unrelated types of 
chromosomal abnormalities (Grimwade et al., 2010). In a study done by Slovak et al 
2006, patients with t(6;9) responded very poorly to chemotherapy. In another separate 
study, chemotherapy was found to have an adverse effect on patients with abnormal 
3q26 (Lugthart et al., 2008). 
 There are several limitations of using karyotyping as a prognostic tool.  
Unsuccessful cytogenetic analysis and presence of cryptic aberrations are some of the 
limitations (Grimwade & Hills, 2009).  Another factor to be taken into consideration 
is the fact that 40-50% of patients with AML have normal karyotype (Grimwade et al; 
2010, Lin &Smith, 2011; Meng et al., 2013). Therefore, mutations in other genes such 
as Nucleophosmin 1 gene (NPM1), CCAAT/enhancer binding protein alpha (CEBPA) 
and FMS-related Tyrosine Kinase 3 gene (FLT3) have to be taken into account before 
a more comprehensive risk stratification of AML patients could be made (Lin & Smith, 
2011). 
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2.3 Mutations in AML. 
 AML is also represented by a plethora of other genetic mutations. Some of 
these mutations have been documented well and serve as important prognostic 
indicators especially when a normal karyotype is present or the cytogenetic analysis is 
unsuccessful (Lin & Smith, 2011; Marcucci et al., 2011) 
 
2.3.1 Nucleophosmin 1 (NPM1) mutations    
 Nucleophosmin 1 is a nuclear cytoplasmic shuttling phosphoprotein 
(Gianfelici et al., 2012). Nucleophosmin 1 mutation was first discovered by using 
immunohistochemical analysis to observe the abnormal cytoplasmic localization of 
NMP1 protein (Falini et al., 2005). Ever since, more than 50 mutations in exon 12 of 
the NPM1 gene have been reported (Falini et al., 2007). The main function of NPM1 
is to transport pre-ribosomal particles from the nucleus to the cytoplasm. Mutation of 
NPM1 causes this transport pathway to be defective (Lin & Smith, 2011). NPM1 has 
also been shown to interact with CDK2-cyclin E and regulate the ARF-p53 tumor 
suppressor pathway (Falini et al., 2007). 
 This gene mutation is by far the most common mutation in AML and is present 
in almost one third of all patients with de novo AML. This mutation is usually found 
in 45%-64% of patients with normal karyotype and 35-40% of patients with trisomy 
8. Other mutations are usually present with NPM1 as well. Over 40% of patients with 
NPM1 mutations have FLT3-ITD mutations as well, 10% have FLT3-TKD mutations 
and 25% have IDH mutations (Marcucci et al., 2011; Gianfelici et al; 2012). 
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 Patients with NPM1 mutations have good clinical outlook in general 
(Schnittger et al., 2005). However those with accompanying FLT3-ITD mutations 
have a poor prognosis (Dohner et al., 2005; Thiede et al., 2006). 
 
2.3.2 CEBPA mutations 
 The CCAAT/enhancer binding protein alpha (CEBPA) is a key transcription 
factor in haematopoiesis and is involved in granulocyte maturation (Pabst et al., 2001a; 
Marcucci et al., 2011). It is found in about 7% of all patients with de novo AML. It is 
also present in about 10-18% patients with normal karyotype and 40% of patients with 
del 9q (Frohling et al., 2004; Bienz et al., 2005; Ferrara & Schifer, 2013).  
 Mutations are usually found in both the N-terminal and C-terminal of the 
protein and are heterozygous (bi-allelic) in nature. Mutations in the N-terminal 
produce a truncated protein with dominant negative properties. Mutations in the C-
terminal occur at the leucine zipper domain and affects DNA binding as well as 
dimerization properties of the protein (Marcucci et al., 2011). 
 Patients with this mutation, especially those with double mutations (both N and 
C terminal) have a good clinical prognosis (Schlenk et al., 2008; Wouters et al., 2009; 
Dufour et al., 2010). 
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2.3.3 FMS-related tyrosine kinase 3 (FLT-3) mutations 
 FLT-3 protein is a member of the class 3 receptor tyrosine kinase family also 
more commonly known as Platelet-derived growth factor receptors (PDGF-R).  It is 
vital for the survival, proliferation and differentiation of hematopoietic progenitor cells 
(Marcucci et al., 2011).  There are two types of FLT-3 mutations namely FLT- ITD 
mutations and FLT-3 TKD mutations (Ferrara & Schifer; 2013). 
 FLT-3-ITD mutations occur in about 20-25% of all AML patients. It is present 
in about 30-35% of patients with normal karyotype (Ferrara & Schifer, 2013). 
Mutations in FLT-3-ITD occur primarily in the juxta-membrane (JM) region (Lin & 
Smith, 2011). However, ITD mutations have been reported in the tyrosine kinase 1 
(TK1) region as well (Breitenbuecher et al., 2009). 
 FLT-3 TKD mutations are less common and occur in about 5% of all AML 
patients. It is present in 10-14% patients with normal karyotype and 14-24% of patients 
with inv(16) (Marcucci et al.,2011; Ferrara & Schifer, 2013). TKD mutations primarily 
occur in the carboxyl terminal and mostly affect codons 835 and 836 in the form of 
point mutations, small insertions and deletions (Frohling et al., 2005; Dohner & 
Dohner 2008). 
 FLT-3-ITD mutations generally heralds a poor prognosis for the patients even 
in the presence of NPM-1 mutations (Dohner et al., 2005; Dohner & Dohner, 2008; 
Mrozek et al., 2007). The clinical prognosis of FLT-3 TKD mutations are still non 
conclusive (Li et al., 2012). 
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2.3.4 KIT gene mutations 
 KIT protein is a PDGF-R as well. It is important for the survival, differentiation 
and activation of hematopoietic progenitor cells (Marcucci et al., 2011). It is found in 
25-30% of patients with core binding factor (CBF) leukaemia (Paschka, 2008). KIT is 
not only mutated but also highly expressed in CBF leukaemia (Bullinger et al., 2004; 
Valk et al., 2004).  KIT mutations have been associated with poor clinical outcome 
(Marcucci et al., 2011). 
 
2.3.5 Isocitrate Dehydrogenase (IDH1/IDH2) mutations 
 Isocitrate dehydrogenase (IDH1/IDH2) is a metabolic enzyme that converts 
isocitrate to α-ketoglutarate. IDH1 is localized in the cytosol while IDH2 is localized 
in the mitochondria. One arginine mutations has been found in IDH1 
(R132H/C/L/I/S/G/V) while two arginine mutations have been found in IDH2 
(R140Q/W, R172K/M/G/W). IDH 1 R132H amino acid substitution is usually found 
together with NPM1 mutations in AML while IDH2 mutations have a distinct gene 
expression and microRNA profile (Marcucci et al., 2010; Paschka et al., 2010; Boissel 
et al., 2010, Yang et al., 2012).  
 IDH mutations were first discovered in brain tumours (Mardis et al., 2009) and 
only later in AML (Schnittger et al., 2010). IDH mutation is found in 15-20% of all 
AML patients in general. IDH1 mutations are found in 10-16% patients with normal 
karyotype while 10-19% of patients with normal karyotype have IDH2 mutations 
(Marcucci et al., 2010; Paschka et al., 2010). Patients with a combination of IDH and 
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NPM1 mutations have a poor prognosis whereas patients with IDH mutations alone 
tend to have slightly better clinical remission (CR) rates (Marcucci et al., 2010; 
Paschka et al., 2010; Boissel et al., 2010). 
 IDH mutations are distinct in AML as they involve a metabolic enzyme. 
Mutations in IDH render cells with the ability to convert α-ketoglutarate to 2-
hydroxyglutarate (2-HG) which is potential oncogenic substrate (Ward et al., 2010). It 
inhibits α-ketoglutarate dependent dioxygenases such as lysine histone demethylases 
and the ten eleven translocation (Tet) family of DNA hydroxylases which includes 
Tet2. Tet2 mutations are commonly found in myeloid malignancies such as 
myelodysplasia and AML (Mullighan, 2009; Yang et al., 2012) 
  
2.3.6 WT1 mutations 
 WT1 is a transcription factor that is associated with the regulation of apoptosis 
and differentiation in hematopoietic progenitor cells. WT1 mutations occur in about 
10-13% of AML patients with normal karyotype (Paschka et al., 2008; Virappane et 
al., 2008). Single nucleotide polymorphism (SNP) rs16754 in WT1 mutations have 
been shown to be an indicator of poor prognosis (Damm et al., 2010). 
  There have been conflicting results regarding the prognostic value of this 
mutation. Some study groups have shown a poor clinical outcome for subgroup of 
AML patients with this mutation (Paschka et al., 2008; Virappane et al., 2008) while 
others indicate that there is no difference in the clinical outcome of patients with this 
mutation (Gaidzik et al., 2009).  This discrepancy could be due to differences in post-
remission treatment modalities (Marcucci et al., 2011). 
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2.3.7 MLL mutations 
 MLL is a DNA binding protein which induces leukaemia via epigenetic 
regulation of tumor suppressor genes. MLL mutations with partial tandem duplication 
(MLL-PTD) is present in 5-11% of patients with normal karyotype and up to 90% of 
patients with trisomy 11. (Mrozek et al, 2007; Dohner & Dohner, 2008). DNA 
methyltransferase and histone deacetylase (HDAC) inhibitors could serve as an 
alternative treatment for AML patients with this mutation (Marcucci et al., 2011). 
Generally, patients with these mutations have a poor clinical outcome. However, 
recent studies have shown that autologous hematopoietic stem cell (HSC) transplant 
and consolidation cycles of chemotherapy seem to offer a slight benefit to patients with 
this mutation (Mrozek et al, 2007; Dohner & Dohner, 2008). 
2.3.8 Other Mutations in AML 
 There are various other genes that are mutated in AML as well.  These include 
NRAS, TP53, TET2 and ASXL1 genes. NRAS encodes for membrane associated 
proteins involved in proliferation and differentiation while TP53 encodes for the 
tumour suppressor protein p53. TET2 could possibly be involved in epigenetic 
mechanisms while ASXL1 plays an important role in chromatin remodelling (Neubauer 
et al., 2008; Haferlach et al., 2008; Delhommeau et al., 2009; Langemeijer et al., 2009; 
Abdel-Wahab et al., 2009).  
 The mutations mentioned above have not been evaluated thoroughly as a 
prognostic tool as its frequency is relatively low in AML patients. Nonetheless, it is 
important to carry out future clinical trials on these potential biomarkers as they could 
aid in risk stratification of patients with AML (Nibourel et al., 2010; Carbuccia et al., 
2010). 
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2.4 Fusion oncoproteins in AML 
 The first fusion onco-protein (BCR-ABL) was discovered in chronic myeloid 
leukaemia (CML) (Druker, 2008). This led to the research of a myriad of other fusion 
protein in various cancers. The importance of fusion proteins is especially apparent in 
myeloid malignancies and this includes AML (Gianfelici et al., 2012). 
 One of the hallmarks of AML is the formation of leukaemic fusion onco-
proteins. More than 750 chromosomal translocations have been identified to date 
(Mitelman et al., 2009). These proteins are a result of gene rearrangements caused by 
non-random chromosomal translocations (Look, 1997). Leukemic fusion oncoproteins 
primarily interfere with the nuclear receptor signalling and transcriptional program of 
the cell. Other changes that are induced include chromatin modifications and structural 
organization (Scandura et al., 2002; Martens et al., 2010).  
 The four most common oncofusion proteins in AML are PML/RARα, 
AML1/ETO, CBFβ/MYH11 and MLL-fusions. There are other fusion proteins such 
as MOZ-CBP, DEK-CAN and RPN1-EVI1 but these proteins are less prevalent 
(Martens et al., 2010). A list of AML fusion oncoproteins together with their 
chromosomal translocation and prognosis is shown in Table 2.3. 
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Table 2.3: Types of oncofusion proteins in AML (Adapted from Martens et al., 
2010). 
 
 
Translocation Prognosis FAB Oncofusion-
protein 
Prevalence 
in AML 
t(8;21) Favourable M2 AML1/ETO 10%  
t(15;17) Favorable M3 PML-RARα 10%  
inv(16) Favorable M4 CBFβMYH11 5% 
der(11q23) Variable M4/M5 MLL-fusions 4% 
t(9;22) Adverse M1/M2 BCR-ABL1 2% 
t(6;9) Adverse M2/M4 DEK-CAN <1% 
t(1;22) Intermediate M7 OTT-MAL <1% 
t(8;16) Adverse M4/M5 MOZ-CBP <1% 
t(7;11) Intermediate M2/M4 NUP98-
HOXA9 
<1% 
t(12;22) Variable M4/M7 MN1-TEL <1% 
inv(3) Adverse M1/M2/M4/M6/M7 RPN1-EVI1 <1% 
t(16;21) Adverse M1/M2/M4/M5/M7 FUS-ERG <1% 
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2.4.1 PML-RARα t(15;17) 
 Translocation t(15;17) causes the RARα gene from chromosome 17 to fuse with 
the PML gene on chromosome 15. This gene rearrangement causes the formation of 
the fusion protein PML-RARA. This fusion protein is present in up to 95% of patients 
with acute promyelocytic leukaemia (APL). On rarer occasions (~2%), other partner 
genes such as PLZF, NPM1, NuMa and STAT5b fuses with the RARα gene (Martens 
et al., 2010; Gianfelici et al., 2012). 
 RARα is a nuclear receptor which heterodimerizes with retinoid X receptor 
(RXR) and functions as a ligand inducing transcription factor. The absence of a ligand 
causes this complex to repress transcription and condense the chromatin via interaction 
with co-repressors that have histone deacetylase (HDAC) activities. PML-RARα 
fusion protein interacts with RXR via PML coiled-coil domains to form the PML-
RARPML-RARα complex which has a slightly different DNA binding ability. The 
altered DNA binding properties enables this complex to block differentiation and 
promote self-renewal (Melnick & Licht, 1999; Dilworth & Chambon, 2001). 
   AML patients with this subgroup of mutation have been very responsive to 
chemotherapy treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide with 
over 70% success rate (Sanz & Lo-Coco, 2011; Avvisati et al., 2011; Breccia et al., 
2011). This is because ATRA and arsenic has the ability to degrade PML-RARα which 
in turn causes apoptosis and abolishes the self-renewing capability of the leukemic 
cells (Ablain & de The, 2011). 
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2.4.2 AML1/ETO t (8;21) 
 AML1/ETO fusion protein is formed by the chromosomal translocation t 
(8;21). This aberration fuses the region coding for the N-terminal of the AML1 
(RUNX1) on chromosome 21 to almost the entire open reading frame of ETO 
(RUNX1T1) gene on chromosome 8 thus creating the fusion protein AML1/ETO. This 
is the most common chromosomal translocation found in adult AML. The structure 
and function of this versatile oncoprotein will be described further in section 2.7. 
 
2.4.3 CBFβ–MYH11 inv(16) 
 Inv(16) gene rearrangement causes the first 165 amino acid residues of core 
binding factor beta (CBFβ) to fuse with the C-terminal coiled-coil region of a smooth 
muscle myosin heavy chain (MYH11) thus forming the fusion protein CBFβ–MYH11 
(Liu et al.,1993). This fusion protein can cause monocytic and eosinophilic 
differentiation (Martens et al., 2010; Gianfelici et al., 2012). 
 CBFβ–MYH11 contains AML1 binding sites in both the N and C terminal. 
Transcriptional repression is achieved via interactions of AML1 with mSinA and 
Groucho co-repressors. The C-terminal of MYH11 also plays an important role in 
repression by recruiting SIN3A and HDAC8 (Lutterbach et al., 1999; Lutterbach & 
Hiebert, 2000, Lukasik et al., 2002). Subgroup of patients with this mutation have a 
relatively good prognosis (Marcucci et al., 2011; Ferrara & Schifer, 2013). 
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2.4.4 MLL rearrangements 
 MLL fusions are present in about 10% of all acute leukaemias. This include 
acute lymphoblastic leukaemia (ALL), biphenotypic acute leukaemia, infant 
leukaemia and acute myeloid leukaemia (AML) treatment related leukaemia (Eguchi 
et al., 2005). Patients with this subgroup of mutations have a relatively poor clinical 
outlook in AML 
 MLL is important for hematopoiesis and has methyltransferase activity. It 
regulates gene expression via chromatin acetylation, methylation and nucleosome 
modifications (Druker, 2008). 
 The N-terminal of MLL has two DNA binding domains, namely the AT-hook 
region and the CXXC domain. AT- hook domains interacts with menin (MEN1) while 
the CXXC domains recruit HDAC components by binding to CpG dinucleotides thus 
acting as a transcriptional repressor (Zeleznik-Le et al., 1994). 
 The C-terminal region (SET, TAD and PHD fingers) of the MLL gene is 
replaced with a fusion partner of whom more than 70 have been identified to date. The 
most common MLL fusion in AML is MLLT3 (AF9). These fusion partners can either 
be nuclear proteins or cytoplasmic proteins. However, in most cases, the MLL fusion 
partner is a nuclear protein. MLL fusions with cytoplasmic proteins as fusion partners 
have less transforming capabilities and the mechanism of its action is not fully 
understood (Gianfelici et al., 2012). 
 In MLL fusions, the amino terminal (N-terminal) acts as a targeting unit to 
direct the oncoprotein complex while the fusion partner acts as an effector and is 
responsible for transactivation of the complex (Slany et al., 1998; Ayton et al., 2004). 
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 Potential treatment of MLL fusions could involve the disruption of MLL 
protein-protein interactions by targeting menin (MEN1). This could be achieved by 
using peptides and small molecule inhibitors (Grembecka et al., 2010). DNA 
demethylating agents and specific methyltransferase inhibitors such as Dot1L 
inhibitors are some other potentially attractive alternatives (Liedtke & Clearly, 2009; 
Daigle et al., 2011, Daigle et al., 2013).  
 
2.5 AML1: The N-terminal fusion partner of AML1-ETO  
 AML1 is a member of the runt related group of transcription factors (RUNXs).  
Other members of this group include the RUNX2 and RUNX3 proteins. Other names 
for AML1 include RUNX1, CBFA2 and PEBP2αB (Van Wijnen et al., 2004). This 
protein was discovered when studying the chromosomal breakpoint caused by t(8;21) 
chromosomal aberration in AML (Miyoshi et al.,1991). This protein has also been 
proven to be an indispensable component of Drosophila embryogenesis (Nusslein-
Volhard et al., 1984; Kania et al., 1990; Kagoshima et al., 1993). AML1 has also been 
detected as serine and threonine phosphorylated protein (Erickson et al., 1996). 
2.5.1 Structure of AML1 
 AML1 consist of three major domains namely the RUNT domain, the 
transactivation domain and the negative regulatory elements (Meyers et al., 1993; 
Levanon et al., 1998; Petrovick et al., 1998).  
 The RUNT domain occupies 128 amino acid residues on the N-terminal (Exons 
2, 3 and 4). The primary function of this domain is to mediate binding of DNA to core 
binding factor beta; CBF-β (Ogawa et al., 1993; Wang et al., 1993).  
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 The C-terminal of RUNX-1 has three very important regions namely the 
transactivation domain (TD), the NMTS domain and the VWRPY motif. These 
domains act as negative regulatory elements. The transactivation domain is located on 
exon 6 and facilitates protein-protein interactions. Nuclear matrix targeting signal 
(NMTS) domain is a 31 amino acid region which is involved in transcriptional 
activation of target genes (Zeng et al., 1998), while the VWRPY motif which is located 
at the very end of the C-terminal exhibits Groucho and TLE dependent transcriptional 
repressor activity (Aronson et al., 1997; Levanon et al., 1998). Both NTMS domains 
and VWRPY motifs have been shown to be important for T-cell development (Telfer 
et al., 2004). 
 Over 12 mRNA isoforms of AML1 have been described (Levanon et al., 2001). 
However, there are predominantly three major isoforms; AML1a, AML1b and AML1c. 
These isoforms are a consequence of alternative splicing (Miyoshi et al., 1995). 
AML1a is significantly shorter than the rest as it lacks the C-terminal. The C-terminal 
of AML1 has been specifically shown to be important for haematopoiesis as the 
absence of it caused abnormal haematopoiesis (Lam & Zhang, 2012). AML1c is 
transcribed by a promoter situated on the distal region of the AML1 locus while AML1a 
and AML1b is transcribed by a promoter on the proximal region (Tsuzuki et al., 2007; 
Liu et al., 2009). The promoter on the proximal side plays an important role in the 
initial events of hematopoiesis while the distal promoter regulates more mature 
progenitor cells (Sroczynska et al., 2009). 
 
 
 
